As of Wednesday close, Global Cord Blood Corporation’s (NYSE:CO) stock was up $0.2, moving up 4.94 percent to $4.25. The average number of shares traded per day over the past five days has been 149,060 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.04 fall in that time frame. In the last twenty days, the average volume was 86,315, while in the previous 50 days, it was 78,550.
Since last month, CO stock retreated 0.00%. Shares of the company fell to $3.93 on 11/23/21, the lowest level in the past month. A 52-week high of $6.31 was reached on 05/27/21 after having rallying from a 52-week low of $3.46. Since the beginning of this year, CO’s stock price has risen by 14.56% or $0.54, and marked a new high 19 times. However, the stock has declined by -32.65% since its 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Right now, Global Cord Blood Corporation (CO) has a P/E ratio of about 6.44. This is lower than the industry average, which comes in at 35.95 right now. Further, its PE also compares favorably with the overall sector’s trailing 12 months PE ratio, which currently stands at 29.53. Within the last five years, Global Cord Blood Corporation’s PE ratio varied between 50.55 and 4.612. The stock’s beta is 0.35. Besides these, the trailing price-to-sales (P/S) ratio of 2.91, the price-to-book (PB) ratio of 0.73, and the price-to-cash flow ratio of 4.93 may also be considered.
The latest dividend of $0.08 per share was paid out, remained unchanged from last year’s $0.08.
On the profitability front, the trailing twelve-month gross margin is 84.60% percent. In the year ended March 30, EBITDA margin amounted to 51.44%, whereas operating margins totaled 47.60%. Based on annual data, CO earned $149.68 million in gross profit and brought in $177.0 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 10.30%. Return on equity (ROE) for the past 12 months was 11.80%. In the past year, the industry average ROE stood at -2.89.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CO’s revenue rose 2.54% during the quarter, while net income inched up to $177.0 million. While analysts expected Global Cord Blood Corporation to report $0.13 quarterly earnings, the actual figure was $0.04 per share, beating the consensus estimate by -69.20%. During the quarter, the company generated $24.25 million in EBITDA. The liabilities of Global Cord Blood Corporation were 552.84 million at the end of its most recent quarter ended March 30, and its total debt was $1.78 million.
This quick technical analysis looks at Global Cord Blood Corporation’s (CO) price momentum. With a historical volatility rate of 39.39%, the RSI 9-day stood at 51.55% on 24 November.
With respect to its five-day moving average, the current Global Cord Blood Corporation price is down by -0.93% percent or -$0.04. At present, CO shares trade -5.97% below its 20-day simple moving average and -19.81% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.64% below its SMA50 and -2.07% below its SMA200.
Stochastic coefficient K was 30.22% and Stochastic coefficient D was 26.43%, while ATR was 0.19. Given the Stochastic reading of 54.24% for the 14-day period, the RSI (14) reading has been calculated as 48.56%. As of today, the MACD Oscillator reading stands at -0.08, while the 14-day reading stands at -0.12.
ROTH Capital reiterated its a Neutral rating on Global Cord Blood Corporation (NYSE: CO) in a note to investors. The analysts firm has however raised their price target to $7.25, representing a possible 37.04% increase in the stock price. Global Cord Blood Corporation (CO) has been rated Buy by analysts. According to 0 brokerage firms, CO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Global Cord Blood Corporation stock as buy, with 1 recommending it as overweight.
What is CO’s price target for the next 12 months?
With a median target price of $15.00, the current consensus forecast for the stock is $15.00 – $15.00. Based on these forecasts, analysts predict Global Cord Blood Corporation (CO) will achieve an average price target of $15.00.